Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Iltoo Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs).
Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-dose interleukin-2 (ld IL-2) activates and expands Tregs in humans.
Hence, Ld IL-2 in patients in whom the autoimmune process was blocked early by a short treatment (2 months) of cyclosporine should restore immune homeostasis and maintain some insulin production over the long term.
Primary Objective :
Tregs' response profile, after 4 administrations of 1MIU/day of IL-2 (Day 63-66) in patients with recently diagnosed type 1 diabetes who have been treated with ciclosporin for 2 months.
Primary assessment criterion:
Change in Tregs values at D67 compared to D63 (post-ciclosporin values)
Secondary objectives and secondary assessment criteria:
Change in residual insulin secretion
Change in Tregs values at Month 3 (Day 88), Month 6 (Day 179), Month 9 (Day 270), Month 12 (Day 361) and after treatment discontinuation at Month 18 (Day 536) and Month 24 (Day 719) compared to baseline and post-ciclosporin values (Day 63)
Ciclosporin and ILT-101/placebo compliance
Tolerance
Experimental design:
This is a monocentric, randomized, placebo controlled, double-blind trial in parallel-groups, evaluating a treatment by cyclosporine 7mg/kg/day during 2 months followed by ILT-101/placebo, 1 MIU daily for 5 days and 1 MIU every week, during 10 months.
Population involved:
Male or female, aged between 16 and 35 years, with recent diagnosis of type 1 diabetes (< 3 months).
Number of subjects: 24 Inclusion period: 12 months Duration of patient participation: 24 months (treatment period: 12 months, follow-up period: 12months) Total duration of the study: 37 months
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ciclosporin/ILT-101 | Experimental | Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months |
|
| Ciclosporin/placebo | Placebo Comparator | Ciclosporin during 2 months (for all patients) followed by placebo during 10 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cyclosporin | Drug | • Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treg variation | Change in Tregs values at Day 67 compared to Day 63 (post-ciclosporin value) | From Day 63 to Day 67 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 6 | Change in Area under curve (AUC (T0-T120) of serum C-peptide after mixed-meal tolerance test compared to baseline 2. Variation in HbA1c value (in %) 3. Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)]. 4. Change in Insulin requirement (insulin dose in international units per kilogram per 24 h 5. Change in Tregs values (in %/CD4+) at month 3, month 6, month 9, month 12 and after treatment interruption at month 18 and month 24 compared to baseline and post-cyclosporin values (Day 63) |
Not provided
Inclusion Criteria:
• Age at inclusion between ≥ 16 years old (Tanner 5 pubertal stage) and ≤ 45 years old
If the patient is a minor, the signatures of both parents and of the child will be collected (or the legal representative if only one parent is alive).
Exclusion Criteria:
Known contraindications to IL2 treatment:
Known contraindications to treatment with cyclosporine
Presence of unauthorized treatment, i.e. cytotoxic drugs, products known for their impact on blood glucose levels or for their interactions with the treatments under trial
Patients who have received anti-diabetic treatment other than insulin for more than 3 consecutive months.
Anti-thyroperoxidase positive and abnormal TSH and T4 at inclusion
Anti-transglutaminase positive at inclusion
EBV viral load > 2000 IU/ml
CMV viral load > 400 IU/ml
HBV, HCV or HIV infection
Lymphopenia ≤ 1000/ mm3
Presence or history of cancer that has been cured for less than five years, except in situ cervical or basal cell carcinoma in early stage management,
Participation in other intervention research involving humans < 3 months,
Pregnant or breastfeeding women
Lack of social security affiliation (as a beneficiary or assignee)
Vaccination with live attenuated virus during the last 4 weeks before the start of the experimental treatment and during the entire treatment phase.
Patient with active SARS-CoV-2 infection
Patient with chronic respiratory disease
Subject under legal protection (such as tutorship, curatorship, or judicial safeguard)
Subject hospitalized without consent, unable to express consent or deprived of liberty
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David Klatzmann, MD, Ph.D | Contact | 01 42 17 74 61 | +33 | david.klatzmann@sorbonne-universite.fr |
| Roberta Lorenzon, MD | Contact | 01 42 17 65 16 | +33 | roberta.lorenzon@sorbonne-universite.fr |
| Name | Affiliation | Role |
|---|---|---|
| David Klatzmann, MD, Ph.D | APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS | Study Director |
| Agnès Hartmann, MD, Ph.D | APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lorenzon Roberta | Recruiting | Paris | 75013 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016572 | Cyclosporine |
| ID | Term |
|---|---|
| D003524 | Cyclosporins |
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
Single group during ciclosporin treatment and parallel group during ILT-101 treatment
Not provided
Not provided
all participant receive the treatment with Ciclosporin and double Blind for the treatment with IL-2
| ILT101 | Drug | • ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354. |
|
| Placebo | Drug | • Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354. |
|
| up to month 6 |
| Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 12 | Change in Area under curve (AUC (T0-T120) of serum C-peptide after mixed-meal tolerance test compared to baseline 2. Variation in HbA1c value (in %) 3. Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)]. 4. Change in Insulin requirement (insulin dose in international units per kilogram per 24 h 5. Change in Tregs values (in %/CD4+) at month 3, month 6, month 9, month 12 and after treatment interruption at month 18 and month 24 compared to baseline and post-cyclosporin values (Day 63) | up to month 12 |
| Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 24 | Change in Area under curve (AUC (T0-T120) of serum C-peptide after mixed-meal tolerance test compared to baseline 2. Variation in HbA1c value (in %) 3. Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)]. 4. Change in Insulin requirement (insulin dose in international units per kilogram per 24 h 5. Change in Tregs values (in %/CD4+) at month 3, month 6, month 9, month 12 and after treatment interruption at month 18 and month 24 compared to baseline and post-cyclosporin values (Day 63) | up to month 24 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at day 63, | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to day 63 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 3 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 3 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 6 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 6 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 9 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 9 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 12 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 12 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 18 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 18 |
| Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 24 | Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to baseline | up to month 24 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at day 63 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to day 63 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period up to month 3 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 3 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 6 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 6 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 9 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 9 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 12 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 12 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at day month 18 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 18 |
| Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 24 | Variation in IDAA1c score (IDAA1c score = HbA1c (in %) + [4 × insulin dose (in international units per kilogram per 24 h)] during the treatment period and during the 1 year follow-up period compared to baseline | up to month 24 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at day 30 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to day 30 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at day 63 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to day 63 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 3 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 3 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 6 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 6 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 9 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 9 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 12 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 12 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 18 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 18 |
| Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 24 | Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period compared to baseline | up to month 24 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at day 30 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to day 30 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at day 63 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to day 63 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 3 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 3 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 6 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 6 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 9 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 9 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 12 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 12 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 18 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 18 |
| Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 24 | Change in Tregs values (in %/CD4+) after treatment interruption compared to baseline and post-cyclosporin values | up to month 24 |
| incidence of adverse events at day 30 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to day 30 |
| incidence of adverse events at day 63 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to day 63 |
| incidence of adverse events at month 3 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 3 |
| incidence of adverse events at month 6 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 6 |
| incidence of adverse events at month 9 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 9 |
| incidence of adverse events at month 12 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 12 |
| incidence of adverse events at month 18 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 18 |
| incidence of adverse events at month 24 | incidence of adverse events throughout the study (according to NCI-CTC AE classification) to the Baseline to month 24 | up to month 24 |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D010455 |
| Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |